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  No two brain diseases would seem to 
be more different than Alzheimer 
disease (AD) and fragile X syndrome 
(FXS). AD affects the old, while FXS 
occurs in childhood. AD affects about 
4 million Americans of both sexes, 
while FXS affects fewer than 50,000, 
primarily boys. And while the cause of 
most cases of AD is unknown, the gene 
responsible for virtually every case of 
FXS has been known for over a decade.
    Despite these dissimilarities, the two 
diseases may be more closely linked 
than expected. A new study by Cara 
Westmark and James Malter shows 
that the protein whose absence causes 
FXS is a key translation regulator of a 
protein implicated in AD. 
    AD, the most common 
neurodegenerative disease, is 
characterized by death of neurons 
throughout the brain. A prominent 
feature of brain degeneration in most 
cases is the appearance of amyloid 
plaques. These sticky clumps are largely 
made of a protein fragment called 
beta-amyloid (Aβ). Aβ is cleaved off 
of a larger protein, amyloid precursor 
protein (APP), whose precise function 
is unknown but which is believed to be 
involved in synapse formation during 
development. After APP messenger 
RNA (mRNA) is synthesized, a 
fraction of it remains quiescent 
until the neuron is excited by the 
neurotransmitter glutamate. When that 
occurs, APP synthesis rapidly spikes 
upward.
    FXS, the most common cause of 
inherited mental retardation, occurs 
when a section of the   fmr-1   gene, 
already containing multiple repeats 
of the nucleotides cytosine-guanine-
guanine, expands to more than 200 
repeats. This inhibits transcription 
of the gene. The gene is on the X 
chromosome, meaning boys only have 
one copy. When the mutated and 
silenced form is the only copy, the 
result is FXS, which causes—in addition 
to mental retardation—autistic-like 
behavior, seizures, and a group of 
abnormal physical traits. The   fmr-1   
gene encodes a protein called FMRP, 
whose normal role is to bind mRNA 
and repress its translation. To date, 
over 500 mRNA targets of FMRP have 
been identiﬁ  ed, many of which may be 
involved with synaptic function. 
    FMRP binds with its target mRNAs 
at sites rich in guanine, especially those 
whose RNA can fold into a cage-like 
structure called a guanine quartet (G-
quartet). Therefore, the authors began 
their search for likely FMRP targets by 
focusing on genes with these sequence 
characteristics. Their database searches 
revealed that APP contains such a 
sequence, which suggested it might 
be regulated by FMRP. To show that 
FMRP actually binds to APP mRNA, 
they isolated synaptoneurosomes, 
which contain pre- and post-synaptic 
vesicles, from the mouse brain and 
treated them with antibodies against 
FMRP. When the antibodies were 
isolated, the researchers found they 
had captured not only FMRP, but also 
APP mRNA, indicating the two were 
physically linked together, at least 
indirectly. 
    They next used neurons in culture 
to examine the effect of FMRP on the 
expression of APP. They found that 
both normal mice and mice missing 
the   fmr-1   gene (“knockout” mice) 
expressed APP, but only normal mice 
increased expression in response to 
DHPG, which stimulates the glutamate 
receptor. Thus, it appears that FMRP 
regulates APP production in some 
manner. The results were not due to 
any effect of FMRP on APP mRNA 
stability, the authors found. Instead, 
as expected, FMRP repressed APP 
translation. To show this, the authors 
treated stimulated synaptoneurosomes 
with anti-FMRP antibodies. Unlike 
in resting synaptoneurosomes, 
in which APP mRNA is isolated 
along with FMRP, in stimulated 
synaptoneurosomes, the APP mRNA 
was not captured, indicating it had 
dislodged. Presumably, this rapid 
dissociation of the two is the ﬁ  rst step 
in the stimulus-dependent synthesis of 
APP.
    To determine whether FMRP binds 
directly to APP mRNA, and not to 
some other intermediary, the authors 
digested the FMRP–mRNA complex 
with RNAse, which digests exposed 
RNA while passing over the region 
bound by protein. Their results showed 
that the two did bind directly with each 
other, but to their surprise, the FMRP 
bound a guanine-rich region near, but 
not identical with, the G-quartet region. 
    Finally, the authors showed that the 
brains of   fmr-1   knockout mice, which 
make no FMRP, contain up to 2.8-fold 
more Aβ than those of normal mice, in 
keeping with the loss of translational 
repression. The signiﬁ  cance of this 
result for FXS patients is unknown. 
It suggests patients may be at risk for 
increased amyloid deposits, but very 
few aged brains from FXS patients 
have been analyzed, and no deposits 
have been observed in younger brains. 
Intriguingly, relatives of FXS patients 
with only moderately expanded   fmr-1   
genes are at risk for developing a 
late-onset syndrome of dementia 
and movement disorder (fragile X 
tremor/ataxia syndrome). Whether 
this is a direct result of decreased APP 
repression is unknown as of yet.
    Taken together, these results indicate 
a close relationship between FMRP and 
APP, with FMRP regulating the normal 
excitation-dependent expression of 
APP. Given APP’s probable role in 
synaptic development, it seems likely 
that its dysregulation may be a key 
step in the development of mental 
retardation in FXS. How, or whether, 
this relationship also plays a part in AD 
is much less certain. Nonetheless, given 
APP’s role in plaque formation, further 
understanding of how APP is created is 
likely to lead to new insights into how 
levels of Aβ are controlled, and from 
that, perhaps even how those levels 
might be reduced. 
    Westmark CJ, Malter JS (2007) FMRP 
mediates mGluR5-dependent translation 
of amyloid precursor protein. doi:10.1371/
journal.pbio.0050052 
Protein–RNA Interaction Links Fragile X Syndrome and Alzheimer Disease
 Richard Robinson   |  doi:10.1371/journal.pbio.0050084
March 2007  |  Volume 5  |  Issue 3  |  e84
doi:10.1371/journal.pbio.0050084.g001
  Hot spots in nerve cells are lit up with 
amyloid precursor protein, the parent 
molecule that is chopped up to liberate 
beta-amyloid, which accumulates in 
Alzheimer disease. (Image: Cara J. 
Westmark) 